SOLIRIS® Offers the
Certainty of Consistent Dosing

Plus, a comprehensive support program to assist you and your patients

A reliable dosing schedule from induction through maintenance

RECOMMENDED SOLIRIS® DOSAGE REGIMEN IN ADULTS (≥18 YEARS OF AGE) WITH gMG1

Dosing considerations

  • SOLIRIS® should be administered by a qualified healthcare professional
  • Do not administer as an IV push or bolus injection

Dosing for adult patients with gMG consists of a 4-week initial induction phase followed by dosing every 14 ± 2 days1

  • The SOLIRIS® admixture should be administered by intravenous infusion over 35 minutes in adults via gravity feed, a syringe-type pump, or an infusion pump.
  • Supplemental dosing of SOLIRIS® is required in the setting of concomitant support with plasmapheresis or plasma exchange; or fresh frozen plasma infusion.1 For more information, see the Product Monograph.

SOLIRIS® should be administered at the recommended dosage regimen time points, or within two days of these time points.

Comprehensive support for your patients and your practice

ONESOURCE® offers:

PHYSICIAN AND
PATIENT SUPPORT

  • Vaccination services
  • Prescription renewal reminders
  • Infusion management

REIMBURSEMENT
ASSISTANCE

  • Reimbursement navigation to ensure maximum coverage
  • Co-pay coordination
  • Monitoring of coverage renewals
  • In-office reimbursement support for physicians

NURSING
SERVICES

  • Network of experienced nurses
  • Private ambulatory clinics
  • Assistance with home infusion

PHARMACY
SERVICES

  • Drug delivery services
  • Pharmacy and distribution coordination
  • Specialty medication expertise

Rachel's story with gMG and SOLIRIS®

“My case manager from OneSource® was in contact with me weekly. She basically was there for me, just to help me with my questions.”
- Rachel, SOLIRIS® patient
Play video
Access SOLIRIS® resources for your practice

SOLIRIS® (eculizumab) is indicated in adult patients with generalized Myasthenia Gravis (gMG).

SOLIRIS® was studied in clinical trials in patients who were anti-acetylcholine receptor (AChR) antibody positive and refractory, defined as failure of treatment with two or more immunosuppressive therapies (ISTs) either in combination or as monotherapy, or failed at least one IST and required chronic plasmapheresis, plasma exchange (PE), or intravenous immunoglobulin (IVIg) to control symptoms. Patients continued to receive standard therapy throughout the pivotal clinical trial.

SOLIRIS® should be administered by a qualified healthcare professional.

WARNING: SERIOUS MENINGOCOCCAL INFECTIONS

Cases of serious or fatal meningococcal infections have been reported in patients treated with SOLIRIS®. Meningococcal infections may become rapidly life-threatening or fatal if not recognized and treated early.

  • Comply with the most current National Advisory Committee on Immunization (NACI) recommendations for meningococcal vaccination in patients with complement deficiencies.
  • All patients must be vaccinated with meningococcal vaccines prior to, or at the time of, initiating SOLIRIS®, unless the risks of delaying SOLIRIS® therapy outweigh the risks of developing a meningococcal infection; revaccinate according to current medical guidelines for vaccine use.
  • All patients must be monitored for early signs of meningococcal infections, evaluated immediately if infection is suspected, and treated with antibiotics, if necessary.

Vaccination may not prevent all meningococcal infections.

Contraindications

Do not initiate SOLIRIS® therapy in patients:

  • With unresolved Neisseria meningitidis infection.
  • Who are not currently vaccinated against Neisseria meningitidis (unless they receive prophylactic treatment with appropriate antibiotics until 2 weeks after vaccination).
1. SOLIRIS® Product Monograph. Alexion Pharmaceuticals Inc. March 25, 2021.